Angelique Gougelet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1180054/publications.pdf

Version: 2024-02-01

27 papers	1,056 citations	623734 14 h-index	526287 27 g-index
31 all docs	31 docs citations	31 times ranked	1875 citing authors

#	Article	IF	Citations
1	Noncoding RNAs in liver cancer patients. , 2022, , 343-389.		0
2	Deleting the Î²-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth. Journal of Hepatology, 2022, 77, 424-435.	3.7	17
3	Expression of NKG2D ligands is downregulated by Î²-catenin signalling and associates with HCC aggressiveness. Journal of Hepatology, 2021, 74, 1386-1397.	3.7	37
4	Epigenetic mechanisms of liver tumor resistance to immunotherapy. World Journal of Hepatology, 2021, 13, 979-1002.	2.0	5
5	ARID1A loss in adult hepatocytes activates Î²-catenin-mediated erythropoietin transcription. ELife, 2020, 9, .	6.0	3
6	Non-coding RNAs open a new chapter in liver cancer treatment. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 630-637.	1.5	3
7	Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography. Gastroenterology, 2019, 157, 807-822.	1.3	22
8	Epigenetic modulation of immunity: towards new therapeutic avenues in hepatocellular carcinoma?. Gut, 2019, 68, 1727-1728.	12.1	2
9	The concomitant loss of <scp>APC</scp> and <scp>HNF</scp>4Î± in adult hepatocytes does not contribute to hepatocarcinogenesis driven by Î²â€catenin activation. Liver International, 2019, 39, 727-739.	3.9	3
10	Î²-catenin-activated hepatocellular carcinomas are addicted to fatty acids. Gut, 2019, 68, 322-334.	12.1	94
11	Exosomal microRNAs as a potential therapeutic strategy in hepatocellular carcinoma. World Journal of Hepatology, 2018, 10, 785-789.	2.0	13
12	Upregulation of the imprinted DLK1/DIO3 locus in response to beta-catenin activation: a promising target for HCC treatment. Journal of Hepatology, 2018, 68, S94-S95.	3.7	0
13	Early HCC treatment: a future strategy against interferon/miR-484 axis to revert precancerous lesions?. Gut, 2016, 65, 1073-1074.	12.1	7
14	Hepatocellular carcinoma diagnosis: Circulating microRNAs emerge as robust biomarkers. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 367-369.	1.5	9
15	Antitumour activity of an inhibitor of miR-34a in liver cancer with Î²-catenin-mutations. Gut, 2016, 65, 1024-1034.	12.1	61
16	T-cell factor 4 and Î²-catenin chromatin occupancies pattern zonal liver metabolism in mice. Hepatology, 2014, 59, 2344-2357.	7.3	137
17	MicroRNAs Linking Cancer and Inflammation: Focus on Liver Cancer. , 2014, , 183-208.		3
18	MicroRNA-feedback loop as a key modulator of liver tumorigenesis and inflammation. World Journal of Gastroenterology, 2013, 19, 440.	3.3	10

#	Article	IF	Citations
19	A Complex Interplay between Wnt/Î²-Catenin Signalling and the Cell Cycle in the Adult Liver. International Journal of Hepatology, 2012, 2012, 1-7.	1.1	21
20	Oncogenic Î²-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. Journal of Clinical Investigation, 2012, 122, 586-599.	8.2	155
21	miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas. Sarcoma, 2011, 2011, 1-13.	1.3	15
22	Microâ€RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. International Journal of Cancer, 2011, 129, 680-690.	5.1	129
23	Lymphoma and Myeloma Cell Resistance to Cytotoxic Agents and Ionizing Radiations Is Not Affected by Exposure to Antiâ€“IL-6 Antibody. PLoS ONE, 2009, 4, e8026.	2.5	19
24	Oestrogen receptors pathways to oestrogen responsive elements: The transactivation function-1 acts as the keystone of oestrogen receptor (ER)Î²-mediated transcriptional repression of ERÎ±. Journal of Steroid Biochemistry and Molecular Biology, 2007, 104, 110-122.	2.5	46
25	Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. Journal of Steroid Biochemistry and Molecular Biology, 2005, 94, 111-121.	2.5	49
26	Estrogen receptor Î± and Î² subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2005, 94, 71-81.	2.5	46
27	Various Phosphorylation Pathways, Depending on Agonist and Antagonist Binding to Endogenous Estrogen Receptor Î± (ERÎ±), Differentially Affect ERÎ± Extractability, Proteasome-Mediated Stability, and Transcriptional Activity in Human Breast Cancer Cells. Molecular Endocrinology, 2003, 17, 2013-2027.	3.7	138